Bio­Car­dia un­veils in­ter­im da­ta that led it to stop PhI­II en­roll­ment of heart fail­ure stem cell ther­a­py

Bio­Car­dia dis­closed that its heart fail­ure stem cell ther­a­py failed to hit on all three mea­sures that com­prised the pri­ma­ry end­point of a Phase III study at an in­ter­im analy­sis.

In 102 pa­tients, there was no sta­tis­ti­cal­ly sig­nif­i­cant dif­fer­ence in rates of death, ma­jor car­dio­vas­cu­lar events and per­for­mance on the six-minute walk test (6MWT) at one year be­tween those who got Bio­Car­dia’s treat­ment and a sham, ac­cord­ing to Bio­Car­dia’s press re­lease Tues­day morn­ing.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER